The Leland Stanford Junior University

The Leland Stanford Junior University is a private research university delivering federal research and medical services to civilian agencies as a prime recipient and contractor across grants, federal research contracts, and medical service agreements, with no SBA set-aside designations and a 90% prime footprint across its federal award portfolio.

Stanford operates as a dual-revenue research institution. The university's federal grant activity—the dominant component—spans biomedical research, physical sciences, engineering, and space exploration through NIH, NSF, DOD, NASA, and civilian agency funders. Concurrently, Stanford delivers time-sensitive clinical services to the Department of Veterans Affairs, including human blood products, genomic support, physician services, radiation safety, and neuromonitoring for VISN 21 (VA Palo Alto Health Care System). The institution holds a single-award Indefinite Delivery Contract with VISN 21 (ceiling $6.25 million, through September 2030) for blood and blood-related products, reflecting Stanford's role as both a research partner and healthcare service provider embedded in the VA clinical delivery network. Recent contract awards include a $8.14 million Genomic Support Services delivery order (April 2026), a $871,458 Radiation Safety Services definitive contract (December 2025), and specialty physician services (gastroenterology, neuromonitoring) each valued in the $100K–$400K range, all open-competition, no set-aside.

The grant portfolio dwarfs contract activity in dollar volume and concentration. NIH awards predominate: the National Institutes of Health accounts for 1,764 awards of the top customer base, with notable concentration in the National Heart, Lung, and Blood Institute ($614.6 million combined potential value), National Cancer Institute, National Institute of General Medical Sciences, and National Institute of Mental Health. NSF and NASA round out the top federal research funders. Stanford's grant work spans hypothesis-driven basic biomedical research (cell and gene therapy, immunology, neurobiology), translational research (organoid engineering, precision medicine diagnostics), clinical research infrastructure (cancer registries, longitudinal cohorts), and workforce development (T32 training grants, CAREER awards). Representative grants awarded in 2026 include a $1.79 billion Allergy and Infectious Diseases multi-project award on phage pharmaceuticals (April 2026), a $1.39 billion NSF MRI award for quantum spectroscopy instrumentation (April 2026), and a $3.09 million NIH cooperative agreement on cardiac organoid modeling (March 2026). The recompete cliff is substantial: 969 awards (combined potential value $25.37 billion) reach completion within the next 24 months, indicating significant near-term pipeline renewal pressure across federal research programs.

Customer concentration by award count shows broad federal portfolio reach (256 distinct agencies served) but heavy NIH weighting by grant dollar value. The top five customers account for 37% of awards; by potential value, the top five account for only 4%, reflecting the fragmented, merit-based nature of federal research funding where many agencies and programs co-fund discovery. SCI-reportable federal service contract activity (FY2022–FY2024) totaled $17.8 million invoiced across 64 prime records, with FY2024 reaching $9.9 million and 28.0 FTEs—a small subset of Stanford's total federal engagement, concentrated in clinical and specialized research support services. Hourly rate posture on federal services contracts ranges from $82–$228/hr (10th to 90th percentile, median $115.52/hr), consistent with academic medical center and research-intensive institution labor costs. Subcontractor engagement on SCI-reportable primes averages 1% of hours, with 15 named subcontractors across the dataset, indicating Stanford's role as primarily a direct-delivery performer rather than a subcontracting intermediary.

Stanford's corporate structure lists six named subsidiaries using Stanford's name and business designations, all classified as non-profit, educational, and business entities; Stanford Hospital & Clinics appears as a separate legal entity managing clinical operations and revenue cycles. The university operates its Palo Alto, California campus as the primary federal work location, though grants and research support activities span distributed centers, institutes, and schools across the Stanford ecosystem (School of Medicine, Lucile Packard Children's Hospital, Engineering School, and affiliated research centers including SLAC National Accelerator Laboratory).

Activity trajectory shows strong growth in awarded dollars (2024: 969 awards; 2023: 630; 2022: 596) but slowing velocity in 2025–2026 (770 and 316 awards respectively in source window), likely reflecting data collection lag and award obligating delays rather than true declining demand. Combined potential value across all 14,317 awards in the source dataset is $27.67 billion, with combined obligations of $36.23 billion (131% of potential value), indicating that many grants have been extended, amended upward, or continued beyond initial ceiling estimates. The university neither competes under small-business set-asides nor maintains government-wide contract vehicles (GWACs, IDIQs, or GSA Schedules) in the traditional federal contractor sense; instead, it holds task-order authority under agency-specific vehicles (VA BOAs, Navy IDIQs) where it serves as an established vendor for specialized services. Stanford's federal footprint is thus characterized by high research award diversity (many small-to-medium grants across multiple agencies and disciplines), deep clinical service relationships with the VA system, and an ecosystem of applied research centers (SLAC, medical institutes) that deliver specialized products (isotope analysis, genomic services, photonic devices, organoid therapies) to federal customers on a project basis rather than as a prime systems integrator or large-scale federal contractor.